Revenue Update on Pieris Pharmaceuticals Inc(NASDAQ:PIRS)

Pieris Pharmaceuticals Inc(NASDAQ:PIRS) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $2.726M. Analysts estimated a revenue of $650.000K. The revenues were 319.38% above the estimates. Earnings per share were $-0.16. The reported EPS was below estimates by -6.67%. Analysts had estimated an EPS of $-0.15.

Pieris Pharmaceuticals Inc (PIRS) made into the market gainers list on Fridays trading session with the shares advancing 4.31% or 0.11 points. Due to strong positive momentum, the stock ended at $2.66, which is also near the day’s high of $2.66. The stock began the session at $2.57 and the volume stood at 2,20,910 shares. The 52-week high of the shares is $3.09 and the 52 week low is $1.3. The company has a current market capitalization of $115 M and it has 4,30,58,827 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 15, 2016, Stephen S. Yoder (CEO) purchased 6,000 shares at $1.68 per share price.Also, On Jun 15, 2016, Darlene M Deptula-hicks (CFO) purchased 5,000 shares at $1.66 per share price.On Jun 15, 2016, Louis Matis (SVP, Chief Development Officer) purchased 10,000 shares at $1.70 per share price, according to the Form-4 filing with the securities and exchange commission.

Pieris Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of Anticalin class of biotherapeutics for patients with diseases. The Company is focused on developing two drug candidates PRS-080 and PRS-060. PRS-080 is an Anticalin protein that binds to hepcidin a natural regulator of iron in the blood. PRS-080 has been designed to target hepcidin for the treatment of functional iron deficiency (FID) in anemic patients with chronic kidney disease (CKD) in end-stage renal disease patients requiring dialysis. PRS-060 is a drug candidate that binds to the IL-4RA receptor thereby inhibiting IL-4 and IL-13 two cytokines small proteins mediating signaling between cells within the human body which are mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. It is also developing PRS-110 in cMet-related cancer and PRS-300 series.

Add Comment